Lb Pharmaceuticals (LBRX) Payables (2024 - 2026)

Lb Pharmaceuticals' Payables history runs 3 years deep, the most recent figure standing at $8.3 million for Q1 2026.

• On a quarterly basis, Payables changed N/A year-over-year to $8.3 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.5 million, down 28.07% from the prior year.
• Payables advanced to $8.3 million in Q1 2026 per LBRX's latest filing, from $3.5 million in the prior quarter.
• Across five years, Payables topped out at $8.3 million in Q1 2026 and bottomed at $3.5 million in Q4 2025.
• The 3-year median for Payables is $4.2 million (2024), against an average of $5.0 million.
• Biggest YoY gain for Payables was 28.07% in 2025; the steepest drop was 28.07% in 2025.
• Year by year, Payables stood at $4.8 million in 2024, then retreated by 28.07% to $3.5 million in 2025, then surged by 138.1% to $8.3 million in 2026.
• Per Business Quant, the three latest LBRX Payables figures stand at $8.3 million (Q1 2026), $3.5 million (Q4 2025), and $3.5 million (Q3 2025).